Here’s why H1 results could boost the AstraZeneca share price

The AstraZeneca share price has been a success story in the past five years. With H1 results due, can it keep going?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Female Doctor In White Coat Having Meeting With Woman Patient In Office

Image source: Getty Images

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The AstraZeneca (LSE: AZN) share price has done well in 2024, and it’s up 80% in five years.

So why, a day before H1 results are due on 25 July, do I think we might still be at the start of a bull run that could go on for a decade or more?

Created with Highcharts 11.4.3AstraZeneca Plc PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.co.uk

Valuation

The valuation, to be fair, doesn’t exactly make the stock look screaming cheap. The shares are trading at around 35 times last year’s earnings. And even with earnings growth on the cards, we’d still be looking at a price-to-earnings (P/E) ratio of 28 for the current year. That’s around twice the long-term FTSE 100 average.

Should you invest £1,000 in Nostrum Oil & Gas Plc right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Nostrum Oil & Gas Plc made the list?

See the 6 stocks

And it doesn’t look like we’re going to get rich on the AstraZeneca dividend. Not with a forecast yield of just 1.8%. But that P/E looks low compared to the valuations of some industry peers. Most of those are listed in the US though, where stocks are typically valued on higher multiples.

Still, forecasts would drop the P/E to around 20 by the end of 2026, less than two years away. If the earnings growth trajectory can continue as it’s doing beyond that, the shares could soon look too cheap.

Cash and debt

AstraZeneca’s been on a decade-long programme of building up its drugs pipeline, which takes a huge investment.

And that can saddle a company with a lot of debt. At the end of Q1 (31 March), net debt stood at $26.4bn (£20.5bn). That’s maybe not much for a company with a £190bn market-cap and total 2023 revenue of $45.8bn (£35.5bn).

But I do like what I see when I look at cash flow and debt forecasts. They show free cash flow rising by 55% between 2023 and 2026. And they suggest net debt could drop by 67% in the same timescale.

Pipeline delivering

When Pascal Soriot took the helm in 2012, the company was in a bad way. Blockbuster patents were expiring and generic manufacturers were making all the money.

It was always going to be a decade-plus job to get the research machine back into motion.

At Q1 time, Soriot said: “Our strong pipeline momentum continued and already this year we announced positive trial results for Imfinzi and Tagrisso that were unprecedented in lung cancer […]  We are also looking forward to seeing the results of several other important trials throughout the year.”

Pipeline back to speed? Looks like job done.

What next?

I don’t expect anything dramatic from the H1 figures, but just reiterating full-year guidance might be enough to boost the shares further.

For the long term? Drugs results have been good so far. But it might only take one or two costly failures to drag the profit outlook back down again.

On valuation, I see AstraZeneca as cheap compared to the industry and I think we could be in for good spell. But others will rate it as expensive compared to the FTSE 100. Either way, I’m looking forward to the update.

But this isn’t the only opportunity that’s caught my attention this week. Here are:

5 Shares for the Future of Energy

Investors who don’t own energy shares need to see this now.

Because Mark Rogers — The Motley Fool UK’s Director of Investing — sees 2 key reasons why energy is set to soar.

While sanctions slam Russian supplies, nations are also racing to achieve net zero emissions, he says. Mark believes 5 companies in particular are poised for spectacular profits.

Open this new report5 Shares for the Future of Energy — and discover:

  • Britain’s Energy Fort Knox, now controlling 30% of UK energy storage
  • How to potentially get paid by the weather
  • Electric Vehicles’ secret backdoor opportunity
  • One dead simple stock for the new nuclear boom

Click the button below to find out how you can get your hands on the full report now, and as a thank you for your interest, we’ll send you one of the five picks — absolutely free!

Grab your FREE Energy recommendation now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK has recommended AstraZeneca Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

2 FTSE 100 and FTSE 250 stocks to consider as stock markets plummet!

Looking for lifeboats as growth-crushing trade tariffs loom? Here are two (including a FTSE 100 gold stock) I think merit…

Read more »

Number three written on white chat bubble on blue background
Investing Articles

Just released: the 3 best growth-focused stocks to consider buying in April [PREMIUM PICKS]

Our goal here is to highlight some of our past recommendations that we think are of particular interest today, due…

Read more »

Happy young plus size woman sitting at kitchen table and watching tv series on tablet computer
Investing Articles

£10,000 invested in Watches of Switzerland shares 1 year ago is now worth…

Watches of Switzerland shares have been decimated by Trump’s tariffs on Switzerland. Dr James Fox explores whether this is an…

Read more »

Hand flipping wooden cubes for change wording" Panic " to " Calm".
Investing Articles

Growth stocks are crashing! Here’s what I’m doing now

Our writer shares his thoughts as growth stocks get crushed, as well as a favourite from the Nasdaq that he…

Read more »

Investing Articles

What’s going on with the Nvidia share price now?

The Nvidia share price is tanking. Once the most valuable listed company, Nvidia has seen more than $1trn wiped off…

Read more »

Investing Articles

This FTSE AIM stock has £2.3bn in net cash, and a market cap of £2.4bn!

I love this FTSE AIM stock, but it really hasn’t delivered for me yet. The stock trades with crazily low…

Read more »

Smart young brown businesswoman working from home on a laptop
Investing Articles

Down 15% in a week! Are these 5 FTSE 100 fallers screaming buys as markets plunge?

Five of Harvey Jones's favourite FTSE 100 stocks all have the same thing in common – they've fallen around 15%…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

2 stocks that have been crushed and now offer a ton of value

Edward Sheldon has been scanning the market for stocks that offer value after the sell-off. Here are two shares he…

Read more »